Clinical diagnosis of attention-deficit/hyperactivity disorder in survivors of pediatric brain tumors

• Published in: Journal of neuro-oncology 2019-06, Vol.143 (2), p.305-312
• Main Authors: Shabason, Emily K., Brodsky, Cole, Baran, Julie, Isaac, Lee, Minturn, Jane E., Ginsberg, Jill P., Hobbie, Wendy, Fisher, Michael, Blum, Nathan, Hocking, Matthew C.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity - diagnosis; Attention Deficit Disorder with Hyperactivity - etiology; Attention deficit hyperactivity disorder; Brain cancer; Brain Neoplasms - complications; Brain tumors; Chemotherapy; Child; Child, Preschool; Clinical Study; Diagnosis; Female; Follow-Up Studies; Glioma; Humans; Hyperactivity; Male; Medicine; Medicine & Public Health; Medulloblastoma; Neoplasia; Neurology; Oncology; Pediatrics; Pituitary; Population studies; Prognosis; Radiation therapy; Retrospective Studies; Risk factors; Surgery; Survival Rate; Survivors - statistics & numerical data; Tumors; Young Adult
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-019-03165-4

Purpose Survivors of pediatric brain tumors often have neurodevelopmental late effects, such as inattention. Symptoms may mirror those of attention-deficit/hyperactivity disorder (ADHD), which affects ~ 5–8% of the general population. This retrospective study of survivors followed at a large tertiary care center examined the prevalence of a clinical diagnosis of ADHD, and risk factors associated with ADHD diagnosis and ADHD-related medication use. Methods A retrospective chart review of brain tumor survivors (n = 528), diagnosed between 2000 and 2015, who were at least 6 years old and 2 years from the end of tumor-directed therapy or from diagnosis, if no interventions were received. Clinical and demographic data were extracted from the medical record. Results Survivors were 55.7% male with mean age 8.15 ± 4.4 (0.0–16.0) years at brain tumor diagnosis. The most common diagnoses were low-grade glioma, medulloblastoma, and craniopharyngioma, with 52.5% of tumors supratentorial. Of the survivors, 81.3% received surgery, 40.0% radiation therapy, and 36.6% chemotherapy. Sixty-nine survivors (13.1%) had ADHD diagnoses, 105 (19.9%) had symptoms of ADHD without diagnoses, and 64 (12.1%) had ADHD medication use. ADHD diagnosis was associated with younger age at tumor diagnosis (p = 0.05) and supratentorial tumor location (p = 0.001). ADHD diagnosis was not associated with gender, tumor type, or treatment type. Conclusions Survivors of brain tumors are at increased risk of ADHD and related symptoms. The greatest increase in risk occurs for survivors with diagnoses at younger ages and supratentorial tumors. Additional research is warranted, as select survivors may benefit from behavioral or pharmacologic ADHD treatments to optimize functioning.